In October 2024 the UK government, for example, estimated that obesity cost the UK health service more than 11 billion each year (UK Government)
- To view or add a comment, sign in The rapid evolution of GLP-1 receptor agonists and dual incretin therapies, including Semaglutide and Tirzepatide has significantly transformed the management of diabetes and obesity
The SURPASS 2 trial was a head-to-head comparison with one of the most effective GLP-1 analogues, semaglutide, in patients only on metformin
Out of that number, 103 participants were GLP-1 medication users
View Study [2]"Safety, tolerability, pharmacokinetics, and pharmacodynamics of cagrilintide with semaglutide" Enebo LB et al., 2021 Finding: Phase 1b trial demonstrated that combining cagrilintide with semaglutide 2.4mg resulted in up to 17.1% weight loss at 20 weeks, with the combination being well-tolerated
What remains less certain is how they translate to specific outcomes like muscle gain or fat loss in various populations